Beverly Huss's guest appearances

Beverly Huss

Medsider: Learn from MedTech and HealthTech Experts

The Health Technology Podcast

Eric Stone

Holly Rockweiler

Derek Herrera

Dana Kanze

Kimberly Smith

David Kim

Keith Lurie

Sean Duffy

Vinod Khosla

Jonathan Coe

Stephanie Tilenius

John Simpson

Matt Abrahams

Scott Wolf

John Murphy

OwlTail

Joining Medsider Radio for this episode is Beverly Huss, President and CEO of Qool Therapeutics, a development-stage company working on a novel, non-invasive therapeutic hypothermia device for the preservation of tissue following catastrophic events like a heart attack, stroke, or traumatic brain injury.Previously, Beverly was the CEO of Vibrynt, a start-up medical device company dedicated to creating minimally invasive therapies for patients suffering from morbid obesity. Prior to that, Beverly was the President of Guidant Endovascular Solutions (acquired by Abbott), a medical device company focused on the treatment of cardiovascular and peripheral vascular disease.She holds an M.S. in technology management from Pepperdine University, as well as a B.S. in metallurgical engineering from the University of Illinois. Beverly also has a few patents to her credit in the cardiovascular and obesity medical device arenas.With me on this episode is guest host, Norbert Juist, one of the most honest, genuine, and personable people I know. Norbert runs Sales Performance Resources, where he specializes in recruiting for medtech marketing and sales positions. Prior to this, he was a sales rep at Cordis Endovascular, a spine consultant at Synthes, and a sales rep at Ethicon. Interview Highlights with Beverly Huss The origin story of Qool Therapeutics and how Beverly got involved with the company. The clinical trial strategy that Qool Therapeutics is following and the reasoning for it. Beverly’s strategic approach to making a medical device a reality, including the regulatory, clinical, and reimbursement paths that should be considered. Key learnings from Beverly’s time at Vibrynt.  The “other R&amp;R”: the importance of resilience and relentlessness when you are raising money for a company. How to get the attention of medical device venture capitalists. Critical lessons Beverly throughout her career at ACS and Guidant. Beverly’s favorite books and how they inspire resiliency. The business leaders and mentors that Beverly most admires. Advice Beverly would give to her 30-year old self. See more...

Joining Medsider Radio for this episode is Beverly Huss, President and CEO of Qool Therapeutics, a development-stage company working on a novel, non-invasive therapeutic hypothermia device for the preservation of tissue following catastrophic events like a heart attack, stroke, or traumatic brain injury.Previously, Beverly was the CEO of Vibrynt, a start-up medical device company dedicated to creating minimally invasive therapies for patients suffering from morbid obesity. Prior to that, Beverly was the President of Guidant Endovascular Solutions (acquired by Abbott), a medical device company focused on the treatment of cardiovascular and peripheral vascular disease.She holds an M.S. in technology management from Pepperdine University, as well as a B.S. in metallurgical engineering from the University of Illinois. Beverly also has a few patents to her credit in the cardiovascular and obesity medical device arenas.With me on this episode is guest host, <a href="https://www.linkedin.com/in/norbertjuist/" rel="nofollow" target="_blank">Norbert Juist</a>, one of the most honest, genuine, and personable people I know. Norbert runs Sales Performance Resources, where he specializes in recruiting for medtech marketing and sales positions. Prior to this, he was a sales rep at Cordis Endovascular, a spine consultant at Synthes, and a sales rep at Ethicon. Interview Highlights with Beverly Huss<ul> <li>The origin story of Qool Therapeutics and how Beverly got involved with the company.</li> <li>The clinical trial strategy that Qool Therapeutics is following and the reasoning for it.</li> <li>Beverly’s strategic approach to making a medical device a reality, including the regulatory, clinical, and reimbursement paths that should be considered.</li> <li>Key learnings from Beverly’s time at Vibrynt. </li> <li>The “other R&amp;R”: the importance of resilience and relentlessness when you are raising money for a company.</li> <li>How to get the attention of medical device venture capitalists.</li> <li>Critical lessons Beverly throughout her career at ACS and Guidant.</li> <li>Beverly’s favorite books and how they inspire resiliency.</li> <li>The business leaders and mentors that Beverly most admires.</li> <li>Advice Beverly would give to her 30-year old self.</li> </ul><a href="https://medsider.com/interviews/beverly-huss-qool-therapeutics" rel="nofollow" target="_blank">See more...</a>

Resiliency and Relentlessness are Crucial for Raising Medtech Capital: Interview with Beverly Huss, President and CEO of Qool Therapeutics

Beverly Huss, President &amp; CEO, Qool Therapeutics Beverly Huss joined Qool Therapeutics as President and CEO in September 2013. Previously, Beverly was President and CEO of Vibrynt, Inc. a company that developed a novel minimally invasive therapeutic device for treatment of morbid obesity. Prior to this, Beverly was with Santa Clara, California-based Guidant since 1986, fulfilling a variety of executive roles within the company’s various medical device divisions. She managed the worldwide Endovascular Solutions business as President and quadrupled worldwide revenues to $150 million for the carotid and peripheral vascular business in four years. Prior to this Beverly held several executive level positions as Vice President of Guidant’s Canada and Latin America operations, Vice President of Vascular Intervention Global Marketing and Vice President of the Stent Business Unit where she built the company’s coronary stent business, a market leader for 27 of 28 quarters with revenue growth of zero to $1 billion in three years. Earlier in her career, Beverly held engineering positions at both Honeywell Defense Systems Division and Jones and Laughlin Steel. Additionally, she served as chairman of the Silicon Valley American Heart Association and as a senior advisor to Pervasis Therapeutics, a Cambridge, MA based cell therapy company. Beverly holds a M.S. in technology management from Pepperdine University and a B.S. in metallurgical engineering from the University of Illinois. Beverly has several patents to her credit in the cardiovascular, obesity and temperature management medical device areas. In addition to the Qool Therapeutics, Board, Beverly serves the boards of Accuray, Kalera Medical, and Madorra, and the University of Illinois Material Science and Engineering steering Committee and Biomedical Engineering Steering Committee. She previously served on the boards of Surefire Medical, Ulthera, Dade Behring, Inc., Wright Medical Inc., and Artes Medical. She is a mentor in the Stanford University Biodesign Fellowship Program. Beverly was the recipient of the 2013 University of Illinois College Of Engineering Alumni Award for distinguished leadership in the medical device industry.

Beverly Huss, President &amp; CEO, Qool Therapeutics Beverly Huss joined Qool Therapeutics as President and CEO in September 2013. Previously, Beverly was President and CEO of Vibrynt, Inc. a company that developed a novel minimally invasive therapeutic device for treatment of morbid obesity. Prior to this, Beverly was with Santa Clara, California-based Guidant since 1986, fulfilling a variety of executive roles within the company’s various medical device divisions. She managed the worldwide Endovascular Solutions business as President and quadrupled worldwide revenues to $150 million for the carotid and peripheral vascular business in four years. Prior to this Beverly held several executive level positions as Vice President of Guidant’s Canada and Latin America operations, Vice President of Vascular Intervention Global Marketing and Vice President of the Stent Business Unit where she built the company’s coronary stent business, a market leader for 27 of 28 quarters with revenue growth of zero to $1 billion in three years. Earlier in her career, Beverly held engineering positions at both Honeywell Defense Systems Division and Jones and Laughlin Steel. Additionally, she served as chairman of the Silicon Valley American Heart Association and as a senior advisor to Pervasis Therapeutics, a Cambridge, MA based cell therapy company. Beverly holds a M.S. in technology management from Pepperdine University and a B.S. in metallurgical engineering from the University of Illinois. Beverly has several patents to her credit in the cardiovascular, obesity and temperature management medical device areas. In addition to the Qool Therapeutics, Board, Beverly serves the boards of Accuray, Kalera Medical, and Madorra, and the University of Illinois Material Science and Engineering steering Committee and Biomedical Engineering Steering Committee. She previously served on the boards of Surefire Medical, Ulthera, Dade Behring, Inc., Wright Medical Inc., and Artes Medical. She is a mentor in the Stanford University Biodesign Fellowship Program. Beverly was the recipient of the 2013 University of Illinois College Of Engineering Alumni Award for distinguished leadership in the medical device industry.

Beverly Huss: Leadership Roles in Medtech